These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 26413561)

  • 1. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
    Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
    PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
    Harrison L; Melvin A; Fiscus S; Saidi Y; Nastouli E; Harper L; Compagnucci A; Babiker A; McKinney R; Gibb D; Tudor-Williams G;
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):42-53. PubMed ID: 26322666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand.
    European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) and Early-treated Perinatally HIV-infected Individuals: Improving Childrenʼs Actual Life with Novel Immunotherapeutic Strategies (EPIICAL) study groups
    AIDS; 2019 Jun; 33(7):1155-1165. PubMed ID: 30741823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.
    Cesar C; Jenkins CA; Shepherd BE; Padgett D; Mejía F; Ribeiro SR; Cortes CP; Pape JW; Madero JS; Fink V; Sued O; McGowan C; Cahn P;
    Lancet HIV; 2015 Nov; 2(11):e492-500. PubMed ID: 26520929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
    Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
    PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: An observational cohort study.
    Cao P; Su B; Wu J; Wang Z; Yan J; Song C; Ruan Y; Xing H; Shao Y; Liao L
    Medicine (Baltimore); 2018 Jul; 97(28):e11463. PubMed ID: 29995803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and predictors of virological failure among HIV infected children and adolescents receiving second-line antiretroviral therapy in Uganda, a retrospective study.
    Musiime-Mwase F; Nakanjako D; Kanywa JB; Nasuuna EM; Naitala R; Oceng R; Sewankambo N; Elyanu P
    BMC Infect Dis; 2024 Sep; 24(1):1057. PubMed ID: 39333946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    Alvarez-Uria G; Pakam R; Naik PK; Midde M
    PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.